Regorafenib, sintilimab, and electroacupuncture for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (regorafenib and sintilimab) plus electroacupuncture for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to see if this triple therapy can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 4 colorectal cancer that is MSS (microsatellite stable) – a type that doesn't respond to certain immunotherapies
- You have already tried at least two standard chemotherapy treatments and they stopped working
- You have not taken regorafenib or similar VEGFR inhibitor drugs before
- You are willing to receive electroacupuncture (a gentle therapy using tiny electrical pulses on acupuncture needles)
- You are between 18 and 75 years old, weigh more than 40 kg (88 lbs), and can swallow pills
- Your organs (kidneys, liver, bone marrow, heart) are working well enough, as shown by recent blood tests and a heart scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests regorafenib as a second-line treatment for people with advanced colorectal cancer that has a RAS mutation. It aims to see if this targeted therapy can help when the first treatment stopped working.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a combination of two drugs (cadonilimab plus regorafenib) as a possible third-line option for people with colorectal cancer that has spread to the liver. It is for patients whose cancer is the MSS/pMMR type and who have already tried standard treatments without success.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.